RY10-4, a novel anti-tumor compound, exhibited its anti-angiogenesis activity by down-regulation of the HIF-1α and inhibition phosphorylation of AKT and mTOR

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 6, 2012, Pages 1633-1640

  Liu, Ziwei ^a   Yuan, Qianying ^a   Zhang, Xuenong ^a   Xiong, Chaomei ^a   Xue, Pingping ^a   Ruan, Jinlan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

AKT; Anti angiogenesis; HIF 1 ; MTOR; RY10 4; VEGF

Indexed keywords

2 (1 HYDROXY 4 OXO CYCLOHEXA 2,5 DIENYL)PYRAN 4 ONE; 2 (4 HYDROXYPHENYL) 4H PYRAN 4 ONE; ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RY 10 3; RY 10 4; SEMAXANIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; EMBRYO; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRONES; TOR SERINE-THREONINE KINASES; ZEBRAFISH;

EID: 84863811189     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1873-3     Document Type: Article

References (34)

1. Mohammad AR, Masakazu T (2003) Anti-angiogenic therapy in breast cancer. Biomed Pharmacother 57:463-470
2. Senn HJ (1982) Current status and indications for adjuvant therapy in breast cancer. Cancer Chemother Pharmacol 8:139-150
3. Susumu S, Hiromi J, Kenichi W, Masato T (2011) Does primary tumor resection improve outcomes for patients with incurable advanced breast cancer? Breast 20:543-547
4. Huang XH, Xiong PC, Xiong CM, Cai YL, Wei AH, Wang JP, Liang XF, Ruan JL (2010) In vitro and in vivo antitumor activity of Macrothelypteris torresiana and its acute/subacute oral toxicity. Phytomedicine 17:930-934
5. Yuan QY, Liu ZW, Xiong CM, Wu LQ, Wang JP, Ruan JL (2011) A novel, broad-spectrum antitumor compound containing the 1-hydroxycyclohexa-2, 5-dien-4-one group: the disclosure of a new antitumor pharmacophore in protoapigenone 1. Bioorg Med Chem Lett 21:3427-3430
6. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31
7. Yancopoulos GD, Klagsbrun M, Folkman J (1998) Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 93:661-664
8. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6
9. Parangi S, O'Reilly M, Christofori G et al (1996) Antiangiogenic therapy of transgenic mice impairs de novo tumor-growth. Proc Natl Acad Sci USA 93:2002-2007
10. Harris AL (1997) Antiangiogenesis for cancer therapy. Lancet 349(suppl II):13-15
11. Claffey KP, Robinson GS (1996) Regulation of VEGF/VPF expression in tumor cells: consequences for tumor-growth and metastasis. Cancer Metast Rev 15:165-176
12. Longo R, Gasparini G (2007) Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol 60:151-170
13. Pandit B, Sun YJ, Chen P, Sackett DL, Hu ZG, Rich W, Li PK et al (2006) Structure-activity-relationship studies of conformationally restricted analogs of combretastatin A-4 derived from SU5416. Bioorgan Med Chem 14:6492-6501
14. Xu G, Zhang WH, Betram P, Zheng XF, McLeod H (2004) Pharmacogenomic profiling of the PI3 K/PTEN-Akt-mTOR pathway in common human tumors. Int J Oncol 24:893-900
15. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
16. Datta NS, Long MW (2002) Modulation of MDM2/p53 and cyclin-activating kinase during the megakaryocyte differentiation of human erythroleukemia cells. Exp Hematol 30:158-165
17. Taraboletti G, Giavazzi R (2004) Modelling approaches for angiogenesis. Eur J Cancer 40:881-889
18. Shin DH, Kim JH, Jung YJ, Kim KE, Jeong JM, Chun YS, Park JW (2007) Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett 255:107-116
19. Chuang TC, Hsu SC, Cheng YT, Shao WS, Wu KH, Fang GS, Ou CC, Wang V (2011) Magnolol down-regulates HER2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells. Cancer Lett 311:11-19
20. Lin AS, Kyoko NG, Chang FR, Yu DL, Lee KH et al (2007) First total synthesis of protoapigenone and its analogues as potent cytotoxic agents. J Med Chem 50:3921-3927
21. Chang HL, Wu YC, Su JH, Yeh YT, Yuan SF (2008) Protoapigenone, a novel Xavonoid, induces apoptosis in human prostate cancer cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-Terminal kinase 1/2. J Pharmacol Exp Ther 325:841-849
22. Wei AH, Zhou DN, Xiong CM, Cai YL, Ruan JL (2011) A novel non-aromatic B-ring Xavonoid: isolation, structure elucidation and its induction of apoptosis in human colon HT-29 tumor cell via the reactive oxygen species-mitochondrial dysfunction and MAPK activation. Food Chem Toxicol 49:2445-2452
23. Liu HB, Xiao YL, Xiong CM, Wei AH, Ruan JL (2008) Apoptosis induced by a new Xavonoid in human hepatoma HepG2 cells involves reactive oxygen species-mediated mitochondrial dysfunction and MAPK activation. Eur J Pharmacol 654:209-216
24. Bradshaw TD, Matthews CS, Cookson J et al (2005) Elucidation of thioredoxin as a molecular target for antitumor quinols. Cancer Res 65:3911-3919
25. Chen WY, Hsieh YA, Tsai CI, Kang YF, Chang FR, Wu YC, Wu CC (2011) Protoapigenone, a natural derivative of apigenin, induces mitogen-activated protein kinase-dependent apoptosis in human breast cancer cells associated with induction of oxidative stress and inhibition of glutathione S-transferaseπ. Invest New Drug 29:1347-1359
26. Mayumi O, Hiroto I, Shigeo Y, Daisuke G, Michihiko K et al (1996) Angiogenesis as a new target for cancer treatment. Cancer Chemother Pharmacol 38(Suppl):S78-S82
27. Zhong XS, Zheng JZ, Reed E, Jiang BH (2004) SU5416 inhibited VEGF and HIF-1α expression through the PI3 K/AKT/p70S6K1 signaling pathway. Biochem Biophy Res Co 324:471-480
28. Comito G, Calvani M, Giannoni E, Bianchini F, Chiarugi P et al (2011) HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med 51:893-904
29. Manolescu B, Oprea E, Busu C, Cercasov C (2009) Natural compounds and the hypoxia-inducible factor (HIF) signalling pathway. Biochimie 91:1347-1358
30. Semenza GL (2000) Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol 35(2):71-103
31. Neshat MS, MellinghoV IK, Tran C, Stiles B, Thomas G, Sawyers CL et al (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314-10319
32. Chiang CT, Way TD, Tsai SJ, Lin JK (2007) Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. FEBS Lett 581:5735-5742
33. Liu D, Xu YJ, Rao ZC, Chen ZC (2011) Preparation of anti-HER2 monoclonal antibody-paclitaxel immunoconjugate and its biological evaluation. J Huazhong Univ Sci Technol [Med Sci] 31(6): 735-740
34. Chen HJ, Xiong T, Qu Y, Zhao FY, Ferriero D, Mu D (2012) mTOR activates hypoxia-inducible factor-1α and inhibits neuronal apoptosis in the developing rat brain during the early phase after hypoxia-ischemia. Neurosci Lett 507:118-123